

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
23 June 2022 (23.06.2022)



(10) International Publication Number  
**WO 2022/132195 A2**

(51) International Patent Classification:  
Not classified

(21) International Application Number:  
PCT/US2021/010059

(22) International Filing Date:  
15 December 2021 (15.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/125,833 15 December 2020 (15.12.2020) US  
63/137,097 13 January 2021 (13.01.2021) US  
63/212,991 21 June 2021 (21.06.2021) US  
63/281,022 18 November 2021 (18.11.2021) US

(71) Applicant: **FLAGSHIP PIONEERING INNOVATIONS V, INC.** [US/US]; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US).

(72) Inventors: **WITT, Abigail, Elizabeth**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **FARELI, Jeremiah, Dale**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **SCHEIDEGGER, Adam, Walter**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **SENAPEDIS, Jr., William, Thomas**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **KENNEDY, Jodi, Michelle**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **BELAGHZAL, Houda**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **YARAR, Defne**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US). **LEE, Eugene**; 55 Cambridge Parkway, 8th Floor, Cambridge, MA 02142 (US).

(74) Agent: **KOYFMAN, Hannah, R.** et al.; K&L Gates LLP, One Lincoln Street, State Street Financial Center, Boston, MA 02111 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2022/132195 A2

(54) Title: COMPOSITIONS AND METHODS FOR MODULATION MYC EXPRESSION

(57) Abstract: The present disclosure relates to compositions and methods for reducing expression of MYC gene in a cell. In some embodiments, an expression repressor comprises a targeting moiety that binds a MYC promoter, anchor sequence, or super-enhancer. In some embodiments, the expression repressor comprises an effector moiety that represses transcription or methylates DNA. Systems comprising two expression repressors are also disclosed. The compositions can be used, for example, to treat cancers such as HCC or NSCLC.